Researchers report long-term follow-up results showing no significant difference in oncologic outcomes among partial nephrectomy, radiofrequency ablation, and cryoablation for cT1 renal tumors.
The Food and Drug Administration has approved Bavencio (avelumab; EMD Serono), a programmed death-ligand 1 (PD-L1) blocking antibody, in combination with Inlyta (axitinib; Pfizer), a kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Elevated C-reactive protein levels prior to nephrectomy for renal cell carcinoma is associated with an increased risk of renal impairment, a study found.
In a study, left-sided renal cell carcinoma (RCC) was associated with a 15% to 20% increased risk of dying from the malignancy compared with right-sided RCC.
FDA approved pembrolizumab, a PD-1 inhibitor, in combination with axitinib, a tyrosine kinase inhibitor, for the first-line treatment of advanced renal cell carcinoma.
Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status.
Patients with treatment-naive, intermediate- and poor-risk advanced RCC continue to have superior overall survival with the dual ICI regimen compared with sunitinib alone.
As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib.
Obesity in childhood and adolescence may be related to the disproportionate rise in certain obesity-related cancers in younger adults, according to authors.
An antibody-drug conjugate targeting ectonucleotide pyrophosphatase/phosphodiesterase 3 conjugated to monomethyl auristatin F had some antitumor activity in patients with advanced, metastatic renal cell carcinoma.
